Aquestive Therapeutics Inc
$ 3.94
0.51%
07 Aug - close price
- Market Cap 491,831,000 USD
- Current Price $ 3.94
- High / Low $ 4.04 / 3.87
- Stock P/E N/A
- Book Value -0.27
- EPS -0.64
- Next Earning Report 2026-08-11
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.29 %
- ROE N/A %
- 52 Week High 7.55
- 52 Week Low 2.93
About
Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and marketing various products to address unmet medical needs in the United States and internationally. The company is headquartered in Warren, New Jersey.
Analyst Target Price
$8.89
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-13 | 2026-03-04 | 2025-11-05 | 2025-08-11 | 2025-05-12 | 2025-03-05 | 2024-11-04 | 2024-08-06 | 2024-05-07 | 2024-03-05 | 2023-11-06 | 2023-08-07 |
| Reported EPS | -0.05 | -0.26 | -0.14 | -0.12 | -0.22 | -0.1607 | -0.11 | -0.01 | -0.17 | -0.09 | -0.03 | -0.1 |
| Estimated EPS | -0.13 | -0.13 | -0.13 | -0.17 | -0.16 | -0.1325 | -0.12 | -0.11 | -0.08 | -0.07 | -0.11 | -0.12 |
| Surprise | 0.08 | -0.13 | -0.01 | 0.05 | -0.06 | -0.0282 | 0.01 | 0.1 | -0.09 | -0.02 | 0.08 | 0.02 |
| Surprise Percentage | 61.5385% | -100% | -7.6923% | 29.4118% | -37.5% | -21.283% | 8.3333% | 90.9091% | -112.5% | -28.5714% | 72.7273% | 16.6667% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-11 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -0.1 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: AQST
2026-08-06 07:42:08
AQST is scheduled to announce its financial results after the market closes on August 11. Investors will be closely watching the earnings report for insights into the company's performance and future outlook. This preview serves as a heads-up for those tracking AQST's financial news.
2026-08-04 16:41:20
Bronstein, Gewirtz and Grossman, LLC has announced a class action lawsuit against Aquestive Therapeutics, Inc. (NASDAQ:AQST) and certain officers. The lawsuit alleges that Aquestive Therapeutics made materially false and misleading statements regarding the approval timeline for its drug Anaphylm, specifically related to human factors and regulatory risks. Shareholders who purchased securities between June 16, 2025, and January 8, 2026, are encouraged to join the lawsuit by May 4, 2026, to seek damages.
2026-08-03 10:42:58
Bronstein, Gewirtz & Grossman, LLC is investigating Aquestive Therapeutics, Inc. (NASDAQ:AQST) for potential corporate wrongdoing. The firm encourages stockholders who purchased Aquestive securities before June 16, 2025, and still hold them, to contact them to assist in the investigation. The firm operates on a contingency fee basis, meaning investors incur no direct cost unless the firm is successful in recovering funds.
2026-07-31 05:11:10
This article provides a comprehensive stock analysis of Aquestive Therapeutics Inc (AQST) by TradingKey, detailing its stock score, financial health, valuation, earnings forecast, price momentum, institutional confidence, and risk assessment. The company has healthy fundamentals, high growth potential, and its valuation is considered fairly valued. Despite recent weak market performance, analysts have rated it as a Buy with a significant upside potential.
2026-07-30 20:39:18
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Aquestive Therapeutics, Inc. (AQST) securities who bought shares before June 16, 2025, and still hold them. The investigation concerns whether Aquestive and its officers engaged in corporate wrongdoing. The firm encourages affected investors to contact them to assist with the investigation, with no cost to the investors.
2026-07-29 11:11:08
Aquestive Therapeutics (NASDAQ: AQST) will release its second quarter 2026 financial results and provide business updates after market close on August 11, 2026. The company will then host a conference call for investors on August 12, 2026, at 8:00 a.m. ET to discuss these results and recent developments. Aquestive Therapeutics is a pharmaceutical company focused on advancing medicines through innovative science and delivery technologies, including its proprietary PharmFilm® and AdrenaVerse™ platforms.
